Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2367952
Max Phase: Preclinical
Molecular Formula: C22H37IN7O15P3
Molecular Weight: 859.40
Molecule Type: Small molecule
Associated Items:
ID: ALA2367952
Max Phase: Preclinical
Molecular Formula: C22H37IN7O15P3
Molecular Weight: 859.40
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(CCCCN(C)c1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O)C(=O)CCCNC(=O)CI
Standard InChI: InChI=1S/C22H37IN7O15P3/c1-28(16(32)6-5-7-24-15(31)10-23)8-3-4-9-29(2)20-17-21(26-12-25-20)30(13-27-17)22-19(34)18(33)14(43-22)11-42-47(38,39)45-48(40,41)44-46(35,36)37/h12-14,18-19,22,33-34H,3-11H2,1-2H3,(H,24,31)(H,38,39)(H,40,41)(H2,35,36,37)/t14-,18-,19-,22-/m1/s1
Standard InChI Key: AJTFLTZIQBCRDH-RCAWKPMRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 859.40 | Molecular Weight (Monoisotopic): 859.0605 | AlogP: -0.20 | #Rotatable Bonds: 19 |
Polar Surface Area: 305.76 | Molecular Species: ACID | HBA: 16 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.90 | CX Basic pKa: 4.60 | CX LogP: -4.18 | CX LogD: -9.34 |
Aromatic Rings: 2 | Heavy Atoms: 48 | QED Weighted: 0.04 | Np Likeness Score: 0.23 |
1. Hampton A, Patel AD, Maeda M, Hai TT, Chang CD, Kang JB, Kappler F, Abo M, Preston RK.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 3. Synthesis of adenosine 5'-triphosphate derivatives with N6- or 8-substituents bearing iodoacetyl groups., 25 (4): [PMID:6279844] [10.1021/jm00346a009] |
2. Hampton A, Picker D, Nealy KA, Maeda M.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 4. Interactions of adenosine 5'-triphosphate derivatives with adenylate kinases from Escherichia coli and rat tissues., 25 (4): [PMID:6279845] [10.1021/jm00346a010] |
3. Hampton A, Patel AD, Chawla RR, Kappler F, Hai TT.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases., 25 (4): [PMID:7040662] [10.1021/jm00346a011] |
Source(1):